Bengaluru-based Biocon Ltd. is setting its sights on becoming the world's largest insulin supplier in the coming years. This ambitious goal comes as major pharmaceutical companies increasingly shift their focus and resources toward newer, more profitable glucagon-like peptide-1 (GLP-1) therapies for diabetes and weight loss.
Kiran Mazumdar-Shaw, co-founder and Executive Chairperson of Biocon, stated in an interview that the company sees a substantial opening in the global market. "In five years, we could be the number one insulin company in the world," she said, highlighting Biocon's unique scale to address this emerging opportunity.
Capitalizing on a Shifting Market
Biocon, currently the world's third-largest insulin supplier by volume, has made significant investments in expanding its production capabilities. This strategy directly responds to the evolving landscape of the estimated $30 billion global insulin market.
Historically, giants like Novo Nordisk A/S and Eli Lilly & Co. saw substantial growth from insulin sales. However, these companies are now directing their research and development efforts, along with marketing, towards next-generation metabolic medicines such as GLP-1s, which promise higher growth potential and profit margins.
Rising Global Demand for Insulin
With over 830 million people worldwide living with diabetes, millions depend on insulin for disease management. Demand for insulin is projected to rise, particularly in emerging markets across Asia, Africa, and Latin America, where diabetes prevalence is growing and access to affordable medication remains a critical challenge.
Mazumdar-Shaw described the current situation as a "windfall" for Biocon's insulin business, emphasizing their capacity to fill the void left by larger players. The company is actively exploring partnerships globally, including with facilities specializing in pen and cartridge manufacturing, to further expand its reach and capacity.
A Distinct Market Strategy
Biocon's approach diverges from many Indian and international drugmakers who are intensely pursuing the obesity and diabetes drug segment. While patents for semaglutide – a key ingredient in popular GLP-1 drugs like Novo Nordisk's Wegovy and Ozempic – are beginning to expire in markets such as India and Canada, opening the door for generic versions, Biocon remains cautious.
Mazumdar-Shaw noted that the generic GLP-1 market is becoming increasingly crowded, especially with extremely low prices in India. Consequently, Biocon does not intend to sell generic semaglutide in India but will instead focus on select international markets, including Canada, Latin America, Brazil, the Middle East, and Southeast Asia.
Founded in 1978, Biocon has grown from an industrial enzymes producer to a major player in generic drugs and biosimilars, with a market capitalization exceeding $7 billion. Mazumdar-Shaw's net worth, according to the Bloomberg Billionaires Index, stands at $2.3 billion, primarily from her stakes in Biocon and related entities.